Overview of Delora stop

Delora stop is a pharmaceutical preparation whose core therapeutic agent is Desloratadine, a synthetic compound chemically related to the earlier drug, Loratadine. It is formally classified as a modern, second-generation antihistamine used for the general management of allergic reactions.

Quick Facts

Property	Description
Active ingredient	Desloratadine (INN)
Form	Oral tablet, Oral solution (syrup)
Pharmacological class	Second-generation Antihistamine
Common use	Relief of allergic discomfort
Origin	Synthetic compound

What Type of Medication is Delora stop?

The active ingredient, Desloratadine (INN), functions pharmacologically as a selective H1-receptor antagonist. This classification places it in the category of drugs that specifically block the effect of histamine, the natural substance responsible for triggering allergic symptoms in the body. Desloratadine's action is due to its selective binding to peripheral histamine receptors, which leads to anti-allergic activity. The medicine is designed to work by stopping the trigger of allergy symptoms in the body. Delora stop is characterized by its once-daily efficacy. As a second-generation agent, its mechanism is distinguished from older antihistamines by its design, which minimizes penetration of the central nervous system.

Composition, Forms, and General Purpose

The medication is supplied for oral route of administration as a single-ingredient product, containing only Desloratadine as the therapeutic component. Available dosage forms include the conventional tablet, orally-disintegrating tablet, and oral solution (liquid/syrup). Delora stop offers both a film-coated tablet and a liquid form, catering specifically to patient groups that may have difficulty swallowing. The medication's purpose is to intercept the body’s allergic cascade, helping to suppress symptoms like sneezing, itching, and watery issues, making it suitable for typical use scenarios involving seasonal allergies or year-round sensitivities.

Regulatory References

Desloratadine EPAR (Aerius)

What side effects are possible with Delora stop?

Possible Side Effects and Safety Information

The official safety profile for Delora stop, which contains Desloratadine, classifies adverse reactions primarily based on their documented frequency and the affected body system, adhering to regulatory standards.

Frequency-Classified Adverse Reactions

Adverse events reported in clinical use are categorized in official prescribing information:

Classification	Examples of Documented Reactions
Common	Headache, fatigue, dry mouth
Very Rare	Seizures, hallucinations, tachycardia (rapid heart rate), hepatitis, elevated liver enzymes, anaphylaxis (severe allergic reaction), angioedema (swelling)
Not Known	Jaundice, aggression, increased appetite, weight gain

Safety Constraints and Special Populations

Side effects affect various System-Organ Classes, including the Nervous System (e.g., headache, seizures), Gastrointestinal System (e.g., dry mouth, nausea), Cardiac System (e.g., tachycardia), and Hepatobiliary System (e.g., hepatitis). Certain reactions, such as anaphylaxis, hepatitis, and seizures, are explicitly documented as serious adverse events, although they occur with a very rare frequency.

Official labels outline specific safety constraints. Delora stop is contraindicated in individuals with known hypersensitivity to the active substance, to the excipients, or to the related compound Loratadine. Caution is specifically required for patients with severe renal or hepatic impairment and those with a personal or familial history of seizures.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section summarizes information concerning Delora stop overdosage, strictly based on authoritative government regulatory documents (e.g., FDA, EMA prescribing information).

Documented Overdose Profile

Area of Concern	Official Regulatory Statement
Documented Manifestations	Overdosage may lead to an exaggeration of common adverse effects, including specific central nervous system (CNS) depression, alterations in cardiac rhythm (e.g., QTc prolongation), and hypotension. Specific laboratory findings may also be documented.
Severe Outcomes Risk	The official label documents the potential for severe or life-threatening outcomes, which may include seizures, respiratory depression, coma, or specific organ toxicity, requiring immediate intervention.

Required Emergency Actions

In all suspected cases of Delora stop overdosage, immediate medical attention is required. Official regulatory guidance mandates contacting a certified Poison Control Center or Poison Help line immediately for advice.

Urgent Medical Help is Necessary If: The patient collapses, experiences severe difficulty breathing, has a seizure, or shows signs of profound CNS depression or unresponsive cardiac changes. Do not attempt to treat the overdose at home.

Clinical Management Strategy

Antidote: If a specific pharmacological antidote is known to reverse the effects of Delora stop, it is specified in the official prescribing information. Otherwise, treatment is defined as supportive and symptomatic.

Supportive Measures: Management involves the support of vital functions, close monitoring (such as continuous cardiac monitoring), and specific measures to reduce drug absorption (e.g., activated charcoal, if appropriate for the circumstances and time of ingestion).

Therapeutic Uses of Delora stop

Delora stop, which contains desloratadine, is commonly used in therapeutic contexts to provide symptomatic relief across two primary domains, focusing on conditions characterized by periods of heightened symptoms. This includes allergic rhinitis and chronic idiopathic urticaria.

It is applied across domains where additional symptomatic support is needed, primarily to ease the symptom clusters of allergic rhinitis, including seasonal hay fever and perennial allergy manifestations. It helps address groups of symptoms that may become intense or disruptive, such as excessive sneezing, persistent runny nose, and nasal congestion, as well as intense itching (pruritus) and the appearance of wheals (hives).

This medication is relevant for easing symptoms that interfere with daily comfort. This assistance supports patients during episodes of heightened discomfort, contributing to improved day-to-day comfort and may assist with coping more steadily with symptom fluctuations.

Quick Facts: Symptomatic Support

Symptom Domain	Key Symptom Managed	Primary Context of Use
Dermal	Intense itching (Pruritus)	Recurrent episodes of Chronic Hives (Urticaria)
Respiratory	Nasal discharge and Sneezing	Seasonal or year-round exposure to allergens

Regulatory References

European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Eligibility for Delora stop: Official Regulatory Status

The eligibility profile for Delora stop (Desloratadine) is defined by age restrictions, hypersensitivity warnings, and cautions regarding specific health conditions, as documented in regulatory labeling.

Scope	Eligibility Status
Populations Contraindicated	Patients with known hypersensitivity to the active substance (Desloratadine), the parent compound (Loratadine), or any other ingredient in the formulation.
Standard Approved Age	Adults and adolescents 12 years of age and over for the standard 5 mg tablet dose. Pediatric use is established for children as young as 6 months for certain formulations and indications.
Conditional Use Required	Adult patients with severe renal impairment (kidney disease) or hepatic impairment (liver disease) should use the medicine under a modified schedule (e.g., every other day), as advised by regulators.
Pregnancy and Lactation	Use during pregnancy is not recommended as a precautionary measure due to limited safety data. Since desloratadine passes into human milk, use is not recommended during breastfeeding; a decision to discontinue the drug or nursing must be made.

Key Regulatory Restrictions

The medicine is generally not recommended for children under 12 years for the 5 mg tablet strength. Specific formulations (like orally disintegrating tablets) carry a warning for individuals with Phenylketonuria (PKU). Caution is also advised in patients with a medical or familial history of seizures.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile for Delora stop (Desloratadine) focuses on specific pharmacokinetic alterations and a noted caution regarding alcohol, as documented in government regulatory sources. The single-ingredient formulation has no combinations formally classified as contraindicated due to interaction risk.

Documented Pharmacokinetic Interactions

Specific medicines increase the overall exposure of Desloratadine in the body. Co-administration with the antifungals Ketoconazole or the macrolide antibiotic Erythromycin results in a measurable increase in the plasma concentrations (AUC and Cmax) of Desloratadine and its active metabolite. Minor increases have also been noted when co-administered with Cimetidine (an H2-receptor antagonist) or Fluoxetine (an SSRI). However, regulatory clinical trials did not show a corresponding clinically significant change to the safety profile.

Interaction Type	Interacting Medicines (Examples)
Increased Exposure	Ketoconazole, Erythromycin, Cimetidine, Fluoxetine
Contraindicated Combinations	None documented for this product

Interactions with Food and Alcohol

Food and Juice: The drug's bioavailability is not affected by the co-administration of food or grapefruit juice. No timing separation from meals is required.
Alcohol: Clinical pharmacology trials found that Desloratadine did not potentiate the performance-impairing effects of alcohol. However, due to post-marketing reports of alcohol intolerance and intoxication, caution is recommended if alcohol is taken concomitantly, as advised in the Summary of Product Characteristics.

Mechanism of Action

Delora stop contains desloratadine, which acts as a highly selective inverse agonist at the peripheral histamine H1 receptor (H1 R). The H1 R is a Gq-protein coupled receptor expressed on various cells, including endothelial and smooth muscle cells. Desloratadine exhibits high affinity and occupies the H1 R without being easily displaced. By functioning as an inverse agonist, the molecule not only competitively blocks the binding of the endogenous agonist, histamine, but also shifts the H1 R to an inactive conformation, suppressing the basal constitutive activity of the receptor. This action stabilizes the H1 R in a non-signaling state. The intracellular consequence is the inhibition of the H1 R-mediated downstream cascade, which includes the reduction of Galpha q activation, subsequently decreasing the activity of phospholipase C and the resulting calcium (Ca^2+) mobilization within the cell. The systemic physiological consequence of this antagonism is the prevention of histamine-induced responses, primarily localized to the H1 R-expressing cells in peripheral tissues, leading to modulation of microvascular permeability and smooth muscle contraction.

Dosage and Administration Information

Official Administration Protocol

The medication, which contains Desloratadine, is intended exclusively for the oral route of administration. It is supplied in multiple forms, including a film-coated 5 mg tablet, an orally-disintegrating tablet (ODT), and an oral solution (syrup), to accommodate administration requirements.

The standard labeled regimen for adolescents and adults (12 years and older) is 5 mg taken once daily. This dose is fixed and represents both the standard starting dose and the maximum recommended daily amount for the medication. The drug can be administered without regard to meals, offering flexibility in daily timing.

Usage patterns are defined by the duration of the allergic condition. For intermittent allergic rhinitis (symptoms lasting less than four days a week or four weeks), treatment may be discontinued upon symptom resolution and reinitiated when symptoms recur. For persistent allergic rhinitis, continuous daily administration is the protocol during periods of exposure.

Specific guidance exists for adults with impaired hepatic or renal function, for whom the starting dose is recommended to be taken 5 mg every other day instead of daily. Furthermore, the liquid solution requires accurate measurement with a calibrated device, and a missed dose should not be doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Delora stop

Evidence Base for Allergic Rhinitis

The research for Delora stop in the context of allergic rhinitis—a condition characterized by fluctuating or episodic manifestations like seasonal hay fever and year-round perennial allergies—was primarily developed through short-term, randomized, double-blind, placebo-controlled clinical trials (RCTs). This type of research was developed using study designs characterized by regulators as suitable for initial evaluation and is relevant in trials assessing short-term or episodic symptom patterns.

In these studies, researchers examined changes in how individuals reported their experience of symptoms. The main measurements used in research exploring how symptoms change over time included composite scores like the Total Symptom Score (TSS) and the Total Nasal Symptom Score (TNSS). The findings describe patterns observed in the studies over the short-term treatment periods, focusing on outcomes related to physical discomfort and changes in daily functioning or activity level.

Evidence Base for Chronic Hives (Urticaria)

For chronic idiopathic urticaria, or chronic hives—a condition involving periods of heightened symptoms—the evidence base relies on Pivotal Phase III randomized, controlled studies. This research was applied in research contexts involving fluctuating or unstable symptoms to understand the medicine's profile during episodes where symptoms become more noticeable.

The studies monitored outcomes related to systemic or functional imbalance, with the primary focus on outcomes related to physical discomfort. The research examined measurements such as the Pruritus (Itching) score and the Urticaria Activity Score (UAS), which is a key metric relevant in evidence describing how symptoms are measured in this condition.

Key Research Gaps and Areas of Uncertainty

The research highlights areas where the evidence is not yet complete. Long-term outcomes are not well characterized in the existing evidence. Since follow-up durations were limited in the initial trials, this applies regarding the sustained use of the medicine over many months or years. The trials also noted an observation related to how the drug is processed by the body: a subset of the population are classified as individuals whose bodies process the medicine differently.

Key Studies & References

Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)

Frequently Asked Questions (FAQ)

Common questions about Delora stop (FAQ)

Q: How quickly can I expect to notice any effects after starting Delora stop?

Official product information indicates that the antihistaminic effects (the action against allergy triggers) have been demonstrated within one hour of a single 5 mg dose. This activity is generally shown to last for up to 24 hours, supporting the once-daily use of the medicine.

Q: Does Delora stop have the same function as other similar drugs I've heard of?

Regulatory documents describe the active ingredient in Delora stop as the major active metabolite of the related drug Loratadine, meaning it has a similar action in the body. Delora stop is considered a modern, second-generation antihistamine, distinguished by its design which results in minimal central nervous system (CNS) penetration compared to older medications in this class.

Q: If I miss a dose of Delora stop, what usually happens?

Official guidance describes the protocol for missed doses: the drug can be taken when remembered, but if the next scheduled dose is near, the missed dose is typically skipped. It is specifically directed in regulatory documents that the dose should not be doubled to make up for a missed one.

Q: Can Delora stop cause changes in my sleep patterns?

Clinical trial data mentions that side effects like insomnia (trouble sleeping) and somnolence (sleepiness) have been reported by users. While the single ingredient product did not show an excess of somnolence compared to a placebo in major trials, the possibility of changes to sleep patterns is noted in official documents.

Q: Does Delora stop interact with common vitamins or herbal supplements?

Regulatory guidance emphasizes the importance of providing a complete list of all products being used—including prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal supplements—for the purposes of safety monitoring.

Q: Is Delora stop safe for older adults (seniors)?

Studies conducted on subjects 65 years and older showed that while the drug's overall exposure in the body was slightly higher than in younger adults, these changes were not considered clinically relevant by regulators. Specific dosage adjustments are not generally mandated for this age group.

Q: Can Delora stop be used by people who have mild kidney issues?

Regulatory documents show that drug exposure is increased in patients with all degrees of renal (kidney) impairment. Official product information notes that patients with any level of renal impairment may require attention, as alternate-day dosing is specifically recommended for those with severe renal impairment.

Q: Can Delora stop affect my ability to drive or operate heavy machinery?

Based on the results of clinical trials, the drug has been found to have no or negligible influence on the ability to drive and use heavy machinery. Official documents state that because individual response to the medicine can vary, establishing one's personal reaction before performing tasks that require mental alertness is advised.

Q: What is the general consensus on how effective Delora stop is for its intended purpose?

In clinical trials for allergic rhinitis, the drug demonstrated the ability to relieve symptoms and provided symptom control for up to 24 hours. The greatest observed improvements were reported by patients in areas related to reducing physical discomfort and mitigating daily activity limitations.

Q: How should I handle minor side effects from Delora stop, like an upset stomach?

Regulatory patient information describes the protocol for minor side effects: a healthcare provider should be contacted if symptoms such as dry mouth or upset stomach are severe, persist, or do not go away.

Q: Does Delora stop accumulate in the body over time?

According to pharmacokinetic data, the amount of drug that accumulates in the body after 14 days of daily dosing is consistent with its half-life (the time it takes for half of the drug to be eliminated). This suggests the drug reaches a predictable level in the body over time.

Q: Can taking Delora stop make me more sensitive to the sun?

Official product labeling notes that the adverse event of photosensitivity (increased skin sensitivity to sunlight) has been reported during the post-marketing experience with the drug. The exact frequency of this reaction is categorized as unknown.

Q: What is the time frame for Delora stop to leave the system after I stop taking it?

The mean elimination half-life of the active ingredient is approximately 27 hours. It is a general pharmacological principle that a substance typically requires several half-lives to be fully cleared from the body.

Q: Can Delora stop be crushed, cut, or chewed?

The official information for film-coated tablets indicates they are intended to be swallowed whole with water. While other forms exist, such as the orally disintegrating tablet (ODT) designed to dissolve on the tongue, the existence of the ODT form suggests that the standard tablet is generally not designed for modification.

Q: Are there any common reasons why Delora stop might not work for someone?

Official documents highlight that a small portion of the population (approximately 7% in studies) are categorized as slow metabolizers of the drug. This genetic variation means their bodies process the medicine differently, which can potentially lead to altered effectiveness or exposure.

Q: What should I do if I think I'm experiencing a rare side effect of Delora stop?

For severe or serious events—such as suspected anaphylaxis, difficulty breathing, or swelling—official guidance describes the protocol: the drug should be discontinued immediately and emergency medical treatment sought.

Q: Is it common to feel jittery or anxious after taking Delora stop?

In post-marketing reports, the adverse event of psychomotor hyperactivity has been reported, although its frequency is unknown. This is a term that may be clinically associated with symptoms such as restlessness, agitation, or a feeling of jitteriness.

Q: What are the main risks associated with taking Delora stop for a long time?

According to the official product monograph, long-term outcomes are not well characterized in the existing research. This is because the follow-up durations in the initial clinical trials were limited, making it an area of ongoing uncertainty regarding sustained use over many months or years.

Q: Can people with mild liver conditions use Delora stop?

Pharmacokinetic studies indicate that drug exposure is increased in patients with all degrees of hepatic (liver) impairment, including mild conditions. Official product information notes that patients with any level of hepatic impairment may require attention, as an alternate-day dosing regimen is specifically recommended for those with severe hepatic impairment.

Q: Does Delora stop contain any common allergens like gluten or lactose?

Official product information confirms that some formulations of the medicine, such as the film-coated tablets, contain lactose as an inactive ingredient. The orally disintegrating tablet (ODT) formulation also carries a warning for individuals with Phenylketonuria (PKU) because it contains aspartame.

How should Delora stop be stored and disposed of?

The storage and disposal of this medicine (Desloratadine) must strictly follow the conditions defined in the official regulatory labeling.

Storage Requirements

The tablets must be stored at controlled room temperature (e.g., 20 C to 25 C). Both the tablets and the oral solution must be protected from moisture and light and kept in the original container.

Handling Requirements	Environmental Protection
Do not freeze the oral solution.	Keep the product out of the sight and reach of children.
Avoid exposure to excessive heat.	Dispose of contents after the labeled shelf-life after opening (liquid form).

Disposal

Unused or expired product must be disposed of according to local regulatory requirements for medicinal waste. It is directed not to be disposed of via wastewater or household trash unless specifically listed for flushing or mixed with undesirable substances as per regulatory guidance.

Delora stop